CSIMarket Company Name, Ticker, Customers, else..
Bioventus Inc   (NASDAQ: BVS)
Other Ticker:  
 


 

Bioventus Inc

BVS's Financial Statements and Analysis



Bioventus Inc reported in the third quarter of 2025 net earnings per share of $0.05 an improvement compare to net loss per share of $-0.37 recorded a year ago and an improvement compare to net loss per share of $-0.04 realized in previous quarter.


third quarter of 2025
Earnings Per Share Revenues
$ 0.05 $  138 Mill
$+0.42     $-12M     -8.24 %



Bioventus Inc 's Revenue fell by -8.24 % in third quarter of 2025 (Sep 27 2025) year on year, to $138 million and advanced by 12.33 % sequentially.


Bioventus Inc is

More on BVS's Income Statement



Bioventus Inc 's net income of $4.006 million in the third quarter of 2025 increased from net loss of $-32.112 million II. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-3.322 million recorded in previous quarter.

More on BVS's Growth

Bioventus Inc Inventories
Inventories grew by 9.89 % to $96 million from II. Quarter a year ago, sequentially inventories rose by 2.37 %. BVS's Cash flow In the third quarter of 2025 company's net cash flow was $19 million, capital expenditures fell by -0.0771,401.30%, to $-1 millions compare to same quarter a year ago

More on BVS's Cash flow Statement


Bioventus Inc does not pay out common stock dividend.

In trailing twelve-month period Bioventus Inc earned $ 0.96 cash per share, on a free-cash flow basis .

Book value grew by 7.15 % sequentially to $3.01 per share.
Tangible Book value grew to $ -2.58 per share from $ -3.30.

Company issued 2.83 million shares or 4.29 % in Sep 27 2025.
Interest Coverage Ratio was 0.9. Debt Coverage Ratio was 0.08.

• More on BVS's Dividends

 Market Capitalization (Millions) 506
 Shares Outstanding (Millions) 69
 Total Debt (Millions $) 323
 Revenue (TTM) (Millions $) 554
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 333




Bioventus Inc does not pay out common stock dividend.

In trailing twelve-month period Bioventus Inc had $ 0.96 cash flow per share, on a free-cash flow basis .

Book value grew by 7.15 % sequentially to $3.01 per share.
Tangible Book value grew to $ -2.58 per share from $ -3.30.

Company issued 2.83 million shares or 4.29 % in Sep 27 2025.
Interest Coverage Ratio was 0.9. Debt Coverage Ratio was 0.08.

• More on BVS's Balance Sheets

 Market Capitalization (Millions) 506
 Shares Outstanding (Millions) 69
 Total Debt (Millions $) 323
 Revenue (TTM) (Millions $) 554
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 333
   


  News about Bioventus Inc Earnings

Bioventus Inc Delivers Strong Performance in First Quarter Financial Results2.



Bioventus Inc (Nasdaq: BVS), a renowned global leader in active healing innovations, recently reported its financial results for the three months ended March 30, 2024. The company also announced a significant milestone in the form of Amendment No. 5 to its Credit and Guaranty Agreement. These developments highlight Bioventus' commitment to enhancing its financial structure and positioning itself for continued growth in the field of regenerative medicine.
Financial Results:
During the last five trading days, Bioventus Inc shares experienced a decline, while over the past year, the shares surged by an impressive 315.37%. These fluctuations indicate some short-term market volatility but showca...

Bioventus Inc. Achieves Remarkable Growth in Fiscal Fourth Quarter of 2023

Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, rec...

Bioventus Inc's Q3 2023 Financial Report Shows Signs of Recovery, But Challenges Persist



Bioventus Inc, a leading player in the Medical Equipment and Supplies sector, recently released its financial performance report for the third quarter of 2023. While the company's strategic moves showcased signs of recovery, the figures reveal a mixed bag of results. This article delves into the highlights of the report and offers insights into the challenges faced by Bioventus Inc in the current market.
Financial Performance Overview
In the fiscal span from July to September 2023, Bioventus Inc experienced a significant improvement in its bottom line. With a loss of $-0.12 per share, the company demonstrated improvement compared to last year's $-1.76 per share loss. Additionally, the short...

Bioventus Inc Soars to New Heights, Achieving Remarkable Financial Growth in Latest Fiscal Year Ending July 01, 2023



Bioventus Inc, a Medical Equipment an...

Bioventus Inc Achieves Record Revenue of $119.059 Million, Propelling Growth and Advancements in Regenerative Medicine

Bioventus Inc is a leading global medical device company specialized in developing, manufacturing, and marketing orthobiologic and surgical products. The company has made significant contributions to the field of regenerative medicine and has pioneered innovative solutions for the treatment of chronic musculoskeletal conditions. Based on its financial performance, Bioventus is well-positioned to continue its mission of transforming patient outcomes and improving their quality of life.
In the financial interval closing April 01 2023, Bioventus Inc reported a total revenue of $119.059 million. This is a significant increase from its previous financial reporting period, indicating a positive growth trajecto...


Date modified: 2025-11-04T21:26:40+00:00




Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2025 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.